1231PD Impact of Crizotinib Treatment on Patient-Reported Symptoms and Quality of Life (QOL) in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC)
Blackhall F, Evans T, Han J, Salgia R, Moro-Sibilot D, Gettinger S, Crino L, Wilner K, Reisman A, Iyer S. 1231PD Impact of Crizotinib Treatment on Patient-Reported Symptoms and Quality of Life (QOL) in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC). Annals Of Oncology 2012, 23: ix402. DOI: 10.1016/s0923-7534(20)33882-5.Peer-Reviewed Original ResearchAdvanced ALK-positive NSCLCGlobal QOLPatient-reported symptomsALK-positive NSCLCQuality of lifePatient-reported outcomesMeaningful improvementsSmall cell lung cancerEffect of crizotinibEfficacy of crizotinibLung cancer moduleMajority of patientsALK-Positive NonLung cancer symptomsCell lung cancerEnd of treatmentHigh response rateHigher symptom severityCrizotinib treatmentCancer QuestionnaireSecondary endpointsMedian ageConclusions TreatmentCancer ModuleQLQ-C30